Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

iStent outcomes after routine cataract surgery

Poster Details

First Author: K.Solomon USA

Co Author(s):    H. Sandoval              

Abstract Details


To evaluate the results of the iStent implanted at time of routine cataract surgery in patients diagnosed with chronic open angle glaucoma.


Carolina Eyecare Physcians, Charleston, SC, USA


Retrospective chart review of patient who underwent uneventful phacoemulsification and iStent Trabecular Micro Bypass (Glaukos Corporation) implantation between August 1, 2012 and January 30, 2013. All patients had one iStent implanted. Preoperative and at least 3-week postoperative intraocular pressure (IOP), number of medications used, and iStent intra and postoperative complications were evaluated. Patients taking combination drops (i.e. Cosopt) were included as using 2 medications.


A total of 33 eyes of 21 patients had complete information and were analyzed. Mean age was 72.3 ḟ7.0 years. Forty-eight percent were females. Mean preoperative IOP was 16.9 ±5.0 mmHg; 86% (18), 9% (2), and 5% (1) were using 1, 2, and 3 medications, respectively. Mean IOP on day 1 after surgery was 18.8 ḟ6.8 mmHg and 16.1 ḟ5.1 mmHg on postoperative day 21. Three eyes of 3 patients who had unilateral implantation of the iStent were still using anti-glaucoma drops. When excluding these 3 eyes, the mean IOP was 15.8 ḟ5.5 mmHg at the 3 weeks postoperative visit. Patients using 2 and 3 medications prior to surgery were not using any medication postoperatively. No intraoperative or postoperative complications were seen.


The use of iStent reduced the IOP to baseline levels without using any anti-glaucoma medication. iStent seems to be a safe alternative to patients with chronic open glaucoma undergoing cataract surgery.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous